1. Academic Validation
  2. Dihydrobenzoxazinone derivatives as aldose reductase inhibitors with antioxidant activity

Dihydrobenzoxazinone derivatives as aldose reductase inhibitors with antioxidant activity

  • Bioorg Med Chem. 2020 Oct 15;28(20):115699. doi: 10.1016/j.bmc.2020.115699.
Huan Chen 1 Xin Zhang 1 Xiaonan Zhang 1 Zhenya Fan 1 Wenchao Liu 1 Yanqi Lei 1 Changjin Zhu 2 Bing Ma 3
Affiliations

Affiliations

  • 1 School of Chemistry and Chemical Engineering, Beijing Institute of Technology, No. 5, Zhongguancun South Street, 100081 Beijing, China.
  • 2 School of Chemistry and Chemical Engineering, Beijing Institute of Technology, No. 5, Zhongguancun South Street, 100081 Beijing, China. Electronic address: zcj@bit.edu.cn.
  • 3 School of Chemistry and Chemical Engineering, Beijing Institute of Technology, No. 5, Zhongguancun South Street, 100081 Beijing, China. Electronic address: mabing@bit.edu.cn.
Abstract

Dihydrobenzoxazinone based design and synthesis produced two series of compounds as Aldose Reductase (ALR2) inhibitor candidates. In particular, phenolic residues were embodied into the compounds for the combination of strengthening the inhibitory acitvity and antioxidant ability to retard the progression of diabetic complications. Most of the derivatives with styryl side chains exhibited excellent activities on selective ALR2 inhibition with IC50 values ranging from 0.082 to 0.308 μM, and {8-[2-(4-hydroxy-phenyl)-vinyl]-2-oxo-2,3-dihydro-benzo[1,4]oxazin-4-yl}-acetic acid (3a) was the most potent. More significantly, most of dihydrobenzoxazinone compounds revealed not only good inhibitory effect on ALR2, but also showed powerful antioxidant activity. Notably, phenolic compound 3a was even comparable to the well-known antioxidant Trolox, confirming that the C8 p-hydroxystyryl substitution was key structure of lowering oxidative stress. Therefore, these results provided an achievement of multifunctional ALR2 inhibitors possessing capacities for both ALR2 inhibition and as antioxidants.

Keywords

Aldose reductase inhibitors; Antioxidant activity; Diabetic complications; Dihydrobenzoxazinone derivatives.

Figures
Products